Live federal data · NADAC weekly · Part D CY24

Probenecid and Colchicine Colchicine

Probenecid and Colchicine vs Colchicine — $124.2M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Alkaloid

Probenecid and Colchicine

First FDA approval: 1982-10-01

Alkaloid

Colchicine

Brand: Colcrys

First FDA approval: 2009-09-01

Lowest NADACAcquisition cost floor across all NDCs

$0.777Per unit

$0.129Per unit

Average NADACAcross all dosage forms and strengths

$0.777Up to $0.777

$1.03Up to $6.04

Generic manufacturersActive ANDA holders — FDA Orange Book

33 total ANDAs filed

1418 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$124.2MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

2.3M1.1M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$53Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes3 manufacturers

Yes14 manufacturers